{
  "ticker": "CUV",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02959546",
  "id": "02959546",
  "pages": 3,
  "price_sensitive": true,
  "date": "20250618",
  "time": "0935",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250618/pdf/06kvpsjj2pqksq.pdf",
  "summary": "**Summary of ASX Announcement:**  \n- **Clinical Trial Results**: SCENESSE\u00ae (afamelanotide) monotherapy failed to demonstrate repigmentation in vitiligo patients in the CUV104 Phase II study.  \n- **Key Implication**: Confirms need for adjunct NB-UVB phototherapy with afamelanotide for efficacy. No further monotherapy studies planned.  \n- **Regulatory Impact**: Results address regulator questions; data will support future marketing submissions for SCENESSE\u00ae in vitiligo.  \n- **Next Steps**: Focus on ongoing Phase III trials (CUV105, CUV107) evaluating SCENESSE\u00ae + NB-UVB combination.  \n\n*No material capital markets/financial information identified.*",
  "usage": {
    "prompt_tokens": 2315,
    "completion_tokens": 157,
    "total_tokens": 2472,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-06-17T23:51:18.172863"
}